Clinical Trial

Psoriatic Immune Response to Tildrakizumab

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-20; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2023-08-25
Trial Details
NCT Number NCT05390515
Lead Sponsor University of California, San Francisco
Collaborators: Sun Pharmaceutical Industries Limited
Conditions Psoriasis Vulgaris
Enrollment 10 participants
Start Date 2022-09-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-04